Dexcom (DXCM) is a publicly traded Healthcare sector company. As of July 5, 2026, DXCM trades at $71.25 with a market cap of $27.49B and a P/E ratio of 33.29. DXCM moved +3.49% today. Year to date, DXCM is +6.25%; over the trailing twelve months it is -14.75%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $83.60. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Deutsche Bank Sets $86 Price Target as FDA Clears DexCom Pediatric CGM: Deutsche Bank initiated coverage on DexCom with a Buy rating and set a price target of $86, implying a potential 24.5% upside. The FDA has expanded DexCom’s Stelo Glucose Biosensor System for over-the-counter pediatric use down to age two, broadening its addressable market for continuous glucose monitoring.
| Metric | Value |
|---|---|
| Price | $71.25 |
| Market Cap | $27.49B |
| P/E Ratio | 33.29 |
| EPS | $2.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.25 |
| 52-Week Low | $54.11 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.66B |
| Net Income | $836.30M |
| Gross Margin | 60.10% |
22 analysts cover DXCM: 0 strong buy, 20 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $83.60.